FibroMAX：迈向一种新型的肝脏疾病通用生物标志物？

FibroMAX: towards a new universal biomarker of liver disease?

作者信息

Morra Rachel, Munteanu Mona, Imbert-Bismut Françoise, Messous Djamila, Ratziu Vlad, Poynard Thierry

机构信息

Groupe Hospitalier Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France.

出版信息

Expert Rev Mol Diagn. 2007 Sep;7(5):481-90. doi: 10.1586/14737159.7.5.481.

DOI:10.1586/14737159.7.5.481

PMID:17892356

Abstract

Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the predictive value and a better benefit-to-risk ratio than biopsy of five combinations of simple serum biochemical markers (the super combination being FibroMAX (BioPredictive, Paris, France) in patients at risk of chronic liver diseases: FibroTest (BioPredictive) for the quantitative assessment of fibrosis; SteatoTest (BioPredictive) for the quantitative assessment of steatosis; ActiTest (BioPredictive) for the quantitative assessment of necroinflammatory activity in chronic viral hepatitis C and B; NashTest (BioPredictive) for the categorical diagnosis of nonalcoholic steatohepatitis; and AshTest for the quantitative assessment of alcoholic steatohepatitis (also known in the USA as HCV-FibroSURE, HBV-FibroSURE, ASH-FibroSURE and NASH-FibroSURE; LabCorp, NC, USA). The possible causes of false-negative and false-positive results are also better identified. These tests, which are now available in 50 countries, can facilitate the screening and management of the most frequent liver diseases.

摘要

在肝活检的非侵入性替代方法中，多项研究已证明，对于慢性肝病风险患者，五种简单血清生化标志物组合（超级组合为FibroMAX（法国巴黎BioPredictive公司））的预测价值及其与活检相比更好的风险效益比：FibroTest（BioPredictive公司）用于纤维化的定量评估；SteatoTest（BioPredictive公司）用于脂肪变性的定量评估；ActiTest（BioPredictive公司）用于慢性丙型和乙型病毒性肝炎坏死性炎症活动的定量评估；NashTest（BioPredictive公司）用于非酒精性脂肪性肝炎的分类诊断；AshTest用于酒精性脂肪性肝炎的定量评估（在美国也称为HCV - FibroSURE、HBV - FibroSURE、ASH - FibroSURE和NASH - FibroSURE；美国北卡罗来纳州LabCorp公司）。假阴性和假阳性结果的可能原因也得到了更好的识别。这些检测方法目前在50个国家可用，有助于对最常见的肝病进行筛查和管理。